0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > OX40 Ligand

OX40 Ligand

Brief Information

Name:Tumor necrosis factor ligand superfamily member 4
Target Synonym:CD252,OX40 ligand,OX40L,TNFSF4,Tumor necrosis factor ligand superfamily member 4,Glycoprotein Gp34,TNF Superfamily Member 4,TXGP1,Tax-Transcriptionally Activated Glycoprotein 1 (34kD),Tumor Necrosis Factor (Ligand) Superfamily, Member 4,Tumor Necrosis Fac
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data

OXL-H5250-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that recombinant Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) can bind to 293T cell overexpressing human OX40. The concentration of OX40 Ligand is 0.003 μg/ml (Routinely tested).

OXL-H5250-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) to 293T overexpressing OX40 was inhibited by increasing concentration of neutralizing anti-OX40 antibody. The concentration of OX40 Ligand used is 0.002 μg/ml. IC50=3.021 μg/ml (Routinely tested).

OXL-H5250-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) on Protein A Biosensor, can bind Human OX40, His Tag (Cat. No. OX0-H5224) with an affinity constant of 2 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

OXL-H52Q8-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human OX40, Avitag,His Tag (Cat. No. TN4-H82E4) on SA Biosensor, can bind Human OX40 Ligand, His Tag (active trimer) (Cat. No. OXL-H52Q8) with an affinity constant of 0.127 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

OX40L,TNFSF4,CD252,Glycoprotein Gp34,TXGP1

Background

Tumor necrosis factor ligand superfamily member 4 (TNFSF4) is also known as glycoprotein Gp34, OX40 ligand (OX40L), TAX transcriptionally-activated glycoprotein 1 and CD252, which belongs to the tumor necrosis factor family. TNFSF4 is the ligand for CD134 and is expressed on such cells as DC2s (a subtype of dendritic cells) enabling amplification of Th2 cell differentiation. The interaction of TNFSF4-TNFSF4 is involved in the pathogenesis of multiple autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), carotid artery disease and cancer. Furthermore, similar to other TNF superfamily members, membrane-bound OX40 Ligand (TNFSF4) exists as a homotrimer. Human TNFSF4 shares 46% amino acid sequence identity with its mouse counterpart.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
KY-1005 KY-1005 Phase 2 Clinical Kymab Autoimmune Diseases; Immune System Diseases; Dermatitis, Atopic Details
mRNA-2416 mRNA-2416; OX40L mRNA - Moderna Therpeutics Phase 2 Clinical Moderna Therapeutics Ovarian Neoplasms; Solid tumours; Lymphoma Details
anti-cancer mRNA therapeutics (Moderna Therapeutics) MT 004; MT-377; MT-380; MT-513; MEDI-1191; mRNA-2095; mRNA-2752; mRNA-IL12-iTu-I-O Phase 1 Clinical Moderna Therapeutics, Astrazeneca Plc Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin Details

This web search service is supported by Google Inc.

totop